MedTrace Logo

Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes

NCT01413204 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 272

Last updated 2026-01-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy and safety of TA-7284 as monotherapy in patients with type 2 Diabetes for 24 weeks administration.

Conditions

Interventions

DRUG

TA-7284 Low

The patients will receive TA-7284-Low orally for 24 weeks.

DRUG

TA-7284 High

The patients will receive TA-7284-High orally for 24 weeks.

DRUG

Placebo

The patients will receive Placebo orally for 24 weeks.

Sponsors & Collaborators

  • Tanabe Pharma Corporation

    lead INDUSTRY

Principal Investigators

  • Nobuya Inagaki, M.D. · Kyoto University, Graduate School of Medicine

  • Kazuoki Kondo, M.D. · Tanabe Pharma Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2012-08-31
Completion
2012-08-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01413204 on ClinicalTrials.gov